Nexvet Biopharma Public Limited Company (NASDAQ:NVET) was established in 2010 and is headquartered in Blackstone, Ireland, with 21 full-time employees. It is a clinical stage pharmaceutical company engaged in animal health drug research .
Update: On July 31, 2017, Zoetis completed the acquisition of Nexvet Biopharma for US$85 million.
Nexvet Biopharma (NVET):
Nexvet Biopharma, like the newly launched JAGX , is a clinical stage biopharmaceutical company focused on animal health. Nexvet relieves and treats osteoarthritis pain in cats and dogs, and treats chronic inflammatory diseases in animals such as atopic dermatitis. The company was first registered in Australia under the name Nexvet Biopharma Pty Ltd (Nexvet Australia) in February 2010. Later, in September 2014, a newly established Irish company Nexvet Biopharma Limited became the parent company of Nexvet Australia and took over All property and debts were re-registered as Nexvet Biopharma Limited and became the current company.
Nexvet Biopharma (NVET) investment:
Nexvet landed on Nasdaq on February 5, 2015. The trading code: NVET, the issue price was US$10, the opening price was US$9.12, and finally closed at US$8.88 per share, a drop of -11.2%, and it broke on the first day. As of the latest closing day (2015-5-21), NVET’s share price was reported at $6.09. After 3 months of listing, it has fallen by -40%.
Nexvet official website: http://www.nexvet.com/
Nexvet American Stock Encyclopedia: https://www.thisyear.com/nvet.html